Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.44 |
| ▸ | PDE4A | P27815 | 3/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4224358 | 0.92 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DALDH1A1 | |
| SCHEMBL4200656 | 0.90 | ALDH1A1 (0.48) | PDE4BPDE4APDE4CPDE4DEGFR | |
| SCHEMBL4855227 | 0.85 | KDM4E (0.45) | PDE4BPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL15509004 | 0.85 | PDE4B (0.59) | PDE4BPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4202107 | 0.85 | PDE4B (0.59) | PDE4BPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4202110 | 0.85 | PDE4B (0.59) | PDE4BPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL16973257 | 0.84 | FFAR4 (0.38) | PDE4B | |
| SCHEMBL16973092 | 0.84 | FFAR4 (0.38) | PDE4B | |
| SCHEMBL3316833 | 0.81 | PIK3CD (0.46) | PIK3CDPIK3CAALDH1A1 | |
| SCHEMBL3317788 | 0.81 | PIK3CD (0.46) | PIK3CDPIK3CAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499482-B2 | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150218092-A1 | PYRROLONE OR PYRROLIDINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2015-08-06 | — | — | US | disclosed |
| EP-2892897-A1 | PYRROLONE OR PYRROLIDINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014039412-A1 | PYRROLONE OR PYRROLIDINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218092-A1 | PYRROLONE OR PYRROLIDINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | PDE4B 1272/4885PIK3CD 4143/4885PIK3CA 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.